Trials / Completed
CompletedNCT00448916
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 1 Month – 16 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Orally-administered pregabalin |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2007-03-19
- Last updated
- 2021-01-25
- Results posted
- 2014-12-02
Locations
18 sites across 3 countries: United States, Mexico, South Korea
Source: ClinicalTrials.gov record NCT00448916. Inclusion in this directory is not an endorsement.